文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

巴瑞替尼对比地塞米松治疗成人COVID-19住院患者(ACTT-4):一项随机、双盲、双安慰剂对照试验

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2022-05-23
一句话结论在需低流量、高流量或无创通气的COVID-19住院患者中,巴瑞替尼联合瑞德西韦与地塞米松联合瑞德西韦第29天无机械通气生存率相似,但地塞米松组不良事件更多。

ACTT-4是一项在美国(60个中心)、韩国(2个)、墨西哥(2个)、新加坡(2个)和日本(1个)共67个中心开展的随机、双盲、双安慰剂对照试验,纳入1010例需低流量(≤15 L/min)、高流量(>15 L/min)或无创机械通气的COVID-19住院成人。患者1:1随机接受巴瑞替尼+瑞德西韦+安慰剂(516例)或地塞米松+瑞德西韦+安慰剂(494例)。第29天无机械通气生存率两组相似(87.0% vs 87.6%;风险差0.6% [95%CI -3.6至4.8];p=0.91),但地塞米松组至少1起不良事件(37% vs 30%;风险差7.5% [1.6至13.3];p=0.014)、治疗相关不良事件(10% vs 4%;风险差6.0% [2.8至9.3];p=0.00041)及3/4级严重或危及生命不良事件(36% vs 28%;风险差7.7% [1.8至13.4];p=0.012)均更多。

要点

  • 需低流量(≤15 L/min)、高流量(>15 L/min)或无创通气的COVID-19住院成人,巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦第29天无机械通气生存率相似(87.0% vs 87.6%;风险差0.6% [95%CI -3.6至4.8];p=0.91)。
  • 地塞米松+瑞德西韦组至少1起不良事件发生率37% vs 巴瑞替尼组30%(风险差7.5% [95%CI 1.6至13.3];p=0.014)。
  • 地塞米松组治疗相关不良事件10% vs 巴瑞替尼组4%(风险差6.0% [95%CI 2.8至9.3];p=0.00041)。
  • 地塞米松组3/4级严重或危及生命不良事件36% vs 巴瑞替尼组28%(风险差7.7% [95%CI 1.8至13.4];p=0.012)。
  • 作者认为,现在可能可以更个体化地选择免疫调节治疗,可考虑副作用特征、给药便利性、费用和患者合并症。

适用人群与场景

  • 住院成人(≥18岁)COVID-19患者,需低流量(≤15 L/min)、高流量(>15 L/min)或无创机械通气给氧,且符合研究纳入标准(男性或非妊娠女性成人≥18岁,实验室确诊SARS-CoV-2感染)。

处置流程与药物剂量

  • 所有患者均接受瑞德西韦(≤10天),并随机接受巴瑞替尼(或匹配口服安慰剂)最长14天,或地塞米松(或匹配静脉安慰剂)最长10天。
  • 随机分组按研究中心和入组时基线序贯评分分层,采用区组设计1:1分配。

研究设计与关键结果

  • 随机、双盲、双安慰剂对照试验,在美国(60个中心)、韩国(2个)、墨西哥(2个)、新加坡(2个)和日本(1个)共67个中心开展;2020年12月1日至2021年4月13日筛查1047例,随机1010例:巴瑞替尼+瑞德西韦+安慰剂组516例(51%),地塞米松+瑞德西韦+安慰剂组494例(49%)。
  • 患者平均年龄58.3岁(SD 14.0);男性590例(58%);白人588例(58%)、黑人188例(19%)、亚洲人70例(7%)、美洲印第安人或阿拉斯加原住民18例(2%);西班牙裔或拉丁裔347例(34%)。
  • 主要终点:第29天无机械通气生存率两组相似,巴瑞替尼组87.0%(95%CI 83.7至89.6),地塞米松组87.6%(95%CI 84.2至90.3);风险差0.6(95%CI -3.6至4.8);p=0.91。
  • 地塞米松组相比巴瑞替尼组状态改善的比值比为1.01(95%CI 0.80至1.27)。
  • 至少1起不良事件:巴瑞替尼组149/503例(30%),地塞米松组179/482例(37%);风险差7.5%(95%CI 1.6至13.3);p=0.014。
  • 至少1起治疗相关不良事件:巴瑞替尼组21/503例(4%),地塞米松组49/482例(10%);风险差6.0%(95%CI 2.8至9.3);p=0.00041。
  • 3或4级严重或危及生命不良事件:巴瑞替尼组143/503例(28%),地塞米松组174/482例(36%);风险差7.7%(95%CI 1.8至13.4);p=0.012。

证据类型、等级与局限

  • 证据类型:随机、双盲、双安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需低流量、高流量或无创通气的COVID-19住院成人中,巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦第29天无机械通气生存率相似。
  • 地塞米松+瑞德西韦组不良事件、治疗相关不良事件及3/4级严重或危及生命不良事件均显著多于巴瑞替尼+瑞德西韦组。
  • 作者认为,现在可能可以更个体化地选择免疫调节治疗,可考虑副作用特征、给药便利性、费用和患者合并症。

指南或共识出处

  • 试验注册号:ClinicalTrials.gov,NCT04640168。
  • 资助:美国国家过敏和传染病研究所(National Institute of Allergy and Infectious Diseases)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.

METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). Hospitalised adults (≥18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or non-pregnant female adults ≥18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received remdesivir (≤10 days) and either baricitinib (or matching oral placebo) for a maximum of 14 days or dexamethasone (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. The trial is registered with ClinicalTrials.gov, NCT04640168.

FINDINGS: Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58·3 years (SD 14·0) and 590 (58%) of 1010 patients were male. 588 (58%) of 1010 patients were White, 188 (19%) were Black, 70 (7%) were Asian, and 18 (2%) were American Indian or Alaska Native. 347 (34%) of 1010 patients were Hispanic or Latino. Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; p=0·91). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; p=0·014). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; p=0·00041). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; p=0·012).

INTERPRETATION: In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered.

FUNDING: National Institute of Allergy and Infectious Diseases.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022. PMID: 35617986. doi:10.1016/S2213-2600(22)00088-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。